Open Accessibility Menu

Coronavirus (COVID-19) Update - We are reopening slowly while keeping your safety in mind.

Click here to learn more.

Clinical Trial Information

A Phase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Castration-Resistant Prostate Cancer

Study Details

A Phase I Study of Entinostat in combination with Enzalutamide for treatment of patients with castration-resistant prostate cancer (CRPC)

Objectives:

  1. Determine the safe dose of Entinostad when given in combination with Enzalutamide in CRPC patients
  2. Determine the safety profiles of the combination of Entinostat and Enzalutamide

Candidates: Patients with Castration-Resistant Prostate Cancer will participate in this phase I study by taking enzalutamide daily and the study drug Entinostat once every 7 days.

Prinicipal Investigator:

Jinqing Lin, MD

Contact Phone:

(202) 994-0450
A Phase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Castration-Resistant Prostate Cancer bmcnamara@mfa.gwu.edu

Interested in More Information

  • Please enter your first name.
  • Please enter your last name.
  • This isn't a valid email address.
    Please enter your email address.
  • This isn't a valid phone number.
    Please enter your phone number.
    You entered an invalid number.
  • Please enter your address.
  • Please enter your city.
  • Please enter your state.
  • Please enter your zip code.
  • (All Uppercase. No Spaces)